Reversing tumor immunosuppression with next-gen GPCR modulation

Today we’re joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter.

We’ll dive into Kainova’s innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics.

We’ll also be taking a look at the broader oncology landscape—what’s hot, who’s investing big, and where the biggest opportunities and challenges lie.

01:09 – Meet Sean Macdonald

05:40 – Kainova's GPCR platform and therapeutic focus

08:57 – The story and meaning behind the Kainova rebrand

10:25 – Series B funding and pipeline programs

16:43 – Exciting trends and innovations in oncology

29:17 – Upcoming milestones and future plans

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• GPCR therapies: Eight promising biotechs hacking the cell signaling pathway
• Episode 182: Building a smart oncology pipeline with Cumulus Oncology
• Episode 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics